Skip to content

Study · Observational study · n = 281 · 2026

6 results

Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.

Giaccari A, Borroni F, Dauriz M, Gioia D, Baptiste P, Bisio A, Lastoria G, Udupa K, Barbagallo M

Diabetes research and clinical practice6 Apr 2026

PMID41951127 (opens in a new tab)DOI10.1016/j.diabres.2026.113244 (opens in a new tab)PepBankPUB-41951127
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, mean HbA1c decreased by 0.7% over 40 weeks of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, HbA1c fell by 0.7% over 40 weeks of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change from V1 to V3
    Study

    n = 281

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Measurements

    HbA1c decrease
    0.7%
    V1 to V3

    Source sentences

    Summary
    mean HbA1c decreased by - 0.7 ± 0.05% (p < 0.0001)
    3 context sentences
    Summary · context
    The primary endpoint was change in glycated haemoglobin (HbA1c) from V1 to V3.
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, mean body weight decreased by 3.6 kg over 40 weeks of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, body weight fell by 3.6 kg over 40 weeks of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change from V1 to V3
    Study

    n = 281

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Measurements

    Body weight decrease
    3.6 kg
    V1 to V3

    Source sentences

    Summary
    mean BW decreased by - 3.6 ± 0.22  kg (p < 0.0001)
    3 context sentences
    Summary · context
    Secondary endpoints included changes in body weight (BW), PROs - assessed by the Diabetes Distress Scale (DDS) and the Dutch Eating Behaviour Questionnaire (DEBQ) - and anthropometric/clinical parameters.
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, Diabetes Distress Scale domain scores decreased on oral semaglutide, indicating reduced diabetes-related distress.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, diabetes-related distress scores fell on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiabetes Distress Scale scores
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores on the DDS domains and the DEBQ (emotional and external eating domains) decreased, indicating reduced diabetes-related distress and improved eating behaviours.
    3 context sentences
    Summary · context
    Secondary endpoints included changes in body weight (BW), PROs - assessed by the Diabetes Distress Scale (DDS) and the Dutch Eating Behaviour Questionnaire (DEBQ) - and anthropometric/clinical parameters.
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, emotional and external eating scores on the DEBQ decreased on oral semaglutide, indicating improved eating behaviours.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, emotional and external eating scores fell on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseEating behaviour (DEBQ emotional and external eating)
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores on the DDS domains and the DEBQ (emotional and external eating domains) decreased, indicating reduced diabetes-related distress and improved eating behaviours.
    3 context sentences
    Summary · context
    Secondary endpoints included changes in body weight (BW), PROs - assessed by the Diabetes Distress Scale (DDS) and the Dutch Eating Behaviour Questionnaire (DEBQ) - and anthropometric/clinical parameters.
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, adverse events were reported by 23.1% of patients on oral semaglutide.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, 23.1% of patients on oral semaglutide reported adverse events.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Measurements

    Adverse event rate
    23.1%
    oral semaglutide

    Source sentences

    Summary
    Adverse events were reported by 23.1% of patients
    2 context sentences
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).
  6. 06HumanObservational studySafety outcome

    In adults with type 2 diabetes switching from DPP-4 inhibitors, no hypoglycaemic episodes were observed on oral semaglutide.

    In plain wordsIn adults with type 2 diabetes switched from DPP-4 inhibitors, no low blood sugar episodes were seen on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycaemic episodes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · oral · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    with no hypoglycaemic episodes observed.
    2 context sentences
    Summary · context
    This 40-week, observational, prospective study included three visits: baseline (V1, OS initiation), intermediate visits (V2.X), and final visit (V3, week 40 ± 4).
    Summary · context
    281 patients were enrolled (mean age 67.5 ± 12.0 years; 55.9% male).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.